Department of Diagnostic Pathology, Fujita Health University School of Medicine, 1-98 Dengakugakubo, Kutsukake-cho, Toyoake, Aichi, 470-1192, Japan,
Curr Infect Dis Rep. 2014 May;16(5):402. doi: 10.1007/s11908-014-0402-4.
Helicobacter pylori infection is one of the most important factors in gastric carcinogenesis in humans. Epidemiological studies have revealed that H. pylori-infected patients develop significantly more gastric cancers than uninfected individuals. In rodent models, H. pylori inoculation causes strong promoting effects in carcinogen-treated animals, whereas the bacterial infection alone causes only hyperplasic, atrophic, and/or metaplastic lesions. In both human and rodent models, eradication of H. pylori helps inhibit gastric carcinogenesis, especially when there is only mild gastric inflammation and no evidence of severe atrophy or intestinal metaplasia. Chemoprevention studies in humans have been reported and have shown the effectiveness of several medications including a cyclooxygenase-2 inhibitor. Candidate chemicals used in rodent models could hopefully be used in humans in the future.
幽门螺杆菌感染是人类胃癌发生的最重要因素之一。流行病学研究表明,幽门螺杆菌感染的患者比未感染的个体更容易发生胃癌。在啮齿动物模型中,幽门螺杆菌接种在致癌物处理的动物中引起强烈的促进作用,而细菌感染本身仅引起增生、萎缩和/或化生病变。在人类和啮齿动物模型中,根除幽门螺杆菌有助于抑制胃癌的发生,特别是在仅有轻度胃炎症且没有严重萎缩或肠化生证据的情况下。已经报道了人类的化学预防研究,并表明了几种药物的有效性,包括环氧化酶-2 抑制剂。在未来,有望在人类中使用在啮齿动物模型中使用的候选化学物质。